NASDAQ · Biotechnology · USD
NuCana plc (NCNA) Stock Analysis
NuCana plc (NCNA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
NCNA Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.00
- Previous Close
- $1.01
- Day's Range
- 0.96–1.01
- 52-Week Range
- 0.95–4.55
- Volume
- 29.62K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 2.31
Valuation
- Market Cap
- $4.00M
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 0.00
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$29.35M
- Shares Outstanding
- 4.16M
- 1-Year Return
- −77.15%
Dividend and dates
- Avg Volume
- 119.68K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, NCNA closed at $0.96, −77.15% over 1 year.
NuCana plc (NCNA) has a market capitalization of $4.00M.
In fiscal 2025, NCNA reported revenue of $0.00.
NCNA Stock Return by Calendar Year
NuCana plc (NCNA) return since Sep 2017: what $10,000 became
- 1 year
- $10,000 $2,285
- −77.15%
- 5 years
- $10,000 $0.75
- −99.99%
- Since Sep 2017
- $10,000 $0.12
- −99.999%
If you had invested $10,000 in NuCana plc (NCNA) at the close on September 28, 2017, the earliest close on record here, it would have been worth $0.12 at the close on October 21, 2026: −99.999% in total, −71.38% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −73.28% |
| 2025 | −98.49% |
| 2024 | −83.92% |
| 2023 | −55.15% |
| 2022 | −72.27% |
| 2021 | −46.99% |
| 2020 | −26.39% |
| 2019 | −57.93% |
| 2018 | +43.42% |
| 2017 (partial year) | −37.40% |
As of October 21, 2026.
NCNA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$29.35M | — |
| 2024 | $0.00 | −$19.00M | — |
| 2023 | $0.00 | −$27.63M | — |
| 2022 | $0.00 | −$32.02M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$20.83M | −$29.35M | — |
| 2024 | $0.00 | — | −$23.01M | −$19.00M | — |
| 2023 | $0.00 | — | −$31.13M | −$27.63M | — |
| 2022 | $0.00 | — | −$43.72M | −$32.02M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe
YahooNuCana Says European Patent Office Grants Patent Covering Composition Of Matter For NUC-7738
BenzingaNuCana Has Been Granted European Patent Number EP3683225 Titled "NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS"
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B